Century Therapeutics (IPSC) stock: insider trades, news & valuation
Net buyingShare price and insider trades
Century Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $97K and 4 sold $86K of IPSC stock on the open market.
Get emailed when insiders cluster-buy stocks like IPSC
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
IPSC insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $10K | 5 |
| Q2 2026 | — | 0 | $12K | 5 |
| Q1 2026 | — | 0 | $46K | 5 |
| Q4 2025 | $97K | 3 | $18K | 5 |
Valuation, profit and volume
Summary
Over the past 12 months, 2 Century Therapeutics, Inc. insiders reported open-market purchases totaling $97K, while 4 insiders reported sales totaling $86K. Among insiders with enough purchase history to measure, Brent Pfeiffenberger (CEO, President) has the highest Insider Score at 100. 0 of 20 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 15SEC | Gregory RussottiSee Remarks | Sell | 2,587509,198 held (−1%) | $1.93 | $5K | -23.8% | — |
| Sep 15SEC | Douglas CarrSvp Finance & Operations | Sell | 1,658502,907 held (−0%) | $1.93 | $3K | -23.8% | — |
| Sep 9SEC | Gregory RussottiSee Remarks | Sell | 534511,785 held (−0%) | $2.05 | $1K | -28.3% | — |
| Sep 9SEC | Douglas CarrSvp Finance & Operations | Sell | 254504,565 held (−0%) | $2.05 | $521 | -28.3% | — |
| Aug 5SEC | Douglas CarrSvp Finance & Operations | Sell | 275504,819 held (−0%) | $1.98 | $544 | -25.8% | — |
| Jun 15SEC | Gregory RussottiSee Remarks | Sell | 2,584512,319 held (−1%) | $2.23 | $6K | -34.1% | — |
| Jun 15SEC | Douglas CarrSvp Finance & Operations | Sell | 1,654505,094 held (−0%) | $2.23 | $4K | -34.1% | — |
| Jun 9SEC | Gregory RussottiSee Remarks | Sell | 524514,903 held (−0%) | $2.11 | $1K | -30.3% | — |
| Jun 9SEC | Douglas CarrSvp Finance & Operations | Sell | 249506,748 held (−0%) | $2.11 | $525 | -30.3% | — |
| May 6SEC | Douglas CarrSvp Finance & Operations | Sell | 264506,997 held (−0%) | $2.34 | $618 | -37.2% | — |
| Mar 16SEC | Gregory RussottiSee Remarks | Sell | 10,076515,427 held (−2%) | $2.55 | $26K | -42.4% | — |
| Mar 16SEC | Douglas CarrSvp Finance & Operations | Sell | 7,043507,261 held (−1%) | $2.55 | $18K | -42.4% | — |
| Mar 11SEC | Gregory RussottiSee Remarks | Sell | 479525,503 held (−0%) | $2.54 | $1K | -42.1% | — |
| Mar 11SEC | Douglas CarrSvp Finance & Operations | Sell | 247514,304 held (−0%) | $2.54 | $627 | -42.1% | — |
| Feb 5SEC | Douglas CarrSvp Finance & Operations | Sell | 323514,551 held (−0%) | $1.82 | $588 | -19.2% | — |
| Dec 29SEC | Chad CowanChief Scientific Officer | Buy | 58,0601,045,087 held (+6%) | $0.85 | $49K | +72.9% | — |
| Dec 16SEC | Brent PfeiffenbergerCEO, President | Buy | 52,0003,322,990 held (+2%) | $0.58 | $30K | +153.4% | 100 |
| Dec 10SEC | Gregory RussottiSee Remarks | Sell | 526390,982 held (−0%) | $0.53 | $279 | +177.4% | — |
| Dec 10SEC | Douglas CarrSvp Finance & Operations | Sell | 257404,874 held (−0%) | $0.53 | $136 | +177.4% | — |
| Nov 24SEC | Chad CowanChief Scientific Officer | Sell | 5,462987,027 held (−1%) | $0.50 | $3K | +194.0% | — |
| Nov 20SEC | Brent PfeiffenbergerCEO, President | Buy | 35,0003,271,453 held (+1%) | $0.50 | $18K | +194.0% | 100 |
| Nov 19SEC | Brent PfeiffenbergerCEO, President | Sell | 32,4563,236,453 held (−1%) | $0.45 | $15K | +226.7% | 100 |
| Nov 5SEC | Douglas CarrSvp Finance & Operations | Sell | 292405,131 held (−0%) | $0.59 | $172 | +149.2% | — |
Insiders at Century Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Brent PfeiffenbergerCEO, President | $48K | $15K | Dec 16, 2025 | 100 |
| Chad CowanChief Scientific Officer | $49K | $3K | Dec 29, 2025 | — |
| Gregory RussottiSee Remarks | — | $40K | Sep 15, 2026 | — |
| Douglas CarrSvp Finance & Operations | — | $29K | Sep 15, 2026 | — |
IPSC stock: common questions
Are Century Therapeutics, Inc. insiders buying IPSC stock?
In the past 12 months, 2 insiders reported open-market purchases of IPSC worth $97K. The latest was Chief Scientific Officer Chad Cowan bought $49K of IPSC at $0.85 — first open-market purchase in our records.
Are Century Therapeutics, Inc. insiders selling IPSC stock?
4 insiders reported sales worth $86K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is IPSC's 52-week range?
Over the past year IPSC has traded between $0.47 and $2.94. It last closed at $1.47 on Oct 9, 2026.